N17350 (NEU-001)
Head & Neck, Skin, Breast Cancers (Solid Tumors)
Pre-clinicalActive
Key Facts
Indication
Head & Neck, Skin, Breast Cancers (Solid Tumors)
Phase
Pre-clinical
Status
Active
Company
About Onchilles Pharma
Onchilles Pharma is a private, preclinical-stage biotech leveraging its proprietary ELANE pathway platform to develop next-generation, selective cytotoxic therapies. The company's approach targets elevated histone H1, a vulnerability shared across cancer types, aiming to deliver potent tumor killing without damaging immune cells. With a pipeline focused on intratumoral and intravenous biologics for multiple solid tumors, Onchilles is preparing for initial clinical trials in 2025/2026, positioning itself at the intersection of targeted cytotoxicity and immunotherapy.
View full company profile